Apalutamide
Apalutamide (INN) (developmental code name ARN-509, also JNJ-56021927) is a non-steroidal antiandrogen that is under development for the treatment of prostate cancer. It is similar to enzalutamide both structurally and pharmacologically, acting as a selective competitive antagonist of the androgen receptor (AR), but shows some advantages, including greater potency and several-fold reduced central nervous system permeation. Apalutamide is currently in phase III clinical trials for castration-resistant prostate cancer.
primaryTopic
Apalutamide
Apalutamide (INN) (developmental code name ARN-509, also JNJ-56021927) is a non-steroidal antiandrogen that is under development for the treatment of prostate cancer. It is similar to enzalutamide both structurally and pharmacologically, acting as a selective competitive antagonist of the androgen receptor (AR), but shows some advantages, including greater potency and several-fold reduced central nervous system permeation. Apalutamide is currently in phase III clinical trials for castration-resistant prostate cancer.
has abstract
Apalutamide (INN) (development ...... ion-resistant prostate cancer.
@en
CAS number
956104-40-8
IUPAC name
4-[7-[6-Cyano-5-(trifluorometh ...... yl]-2-fluoro-N-methylbenzamide
@en
PubChem
thumbnail
Link from a Wikipage to an external page
Wikipage page ID
47,734,223
Wikipage revision ID
742,447,052
ChemSpiderID
28,424,131
elimination half-life
-345600.0
molecular weight
4.77434713e+2
pregnancy category
routes of administration
smiles
StdInChIKey
HJBWBFZLDZWPHF-UHFFFAOYSA-N
subject
hypernym
comment
Apalutamide (INN) (development ...... ion-resistant prostate cancer.
@en
label
Apalutamide
@en
